Share Price, page-7949

Your maths may be correct, but I’m not sure your assumptions are.

According to Acadia, there are 4500 diagnosed individuals with Rett syndrome in the United States.

One of the basic requirements to qualify for health coverage of Daybue is a diagnosis of Rett.

If 75% of the currently diagnosed US Rett population gave Daybue a go, at an average cost of $375,000 per annum, that would be $1.266bn a year. But a dropout rate of 25% (which seems to reflect the real world persistency rate to date) would bring that figure back to $949m, still shy of the $1bn mark.

Of course, increasing the diagnosed US population (which I am sure Acadia is working hard on) as well as adding Canadian Rett patients could boost this figure further.